Valuation: Profound Medical Corp.

Market Cap 356M 255M 221M 207M 189M 24.36B 362M 2.43B 952M 12.19B 959M 938M 40.68B P/E 2026 *
-8.12x
P/E 2027 * -11.9x
Enterprise Value 356M 255M 221M 207M 189M 24.36B 362M 2.43B 952M 12.19B 959M 938M 40.68B EV / Sales 2026 *
9.83x
EV / Sales 2027 * 5.98x
Free-Float
95.93%
Yield 2026 *
-
Yield 2027 * -
1 day-4.51%
1 week-17.18%
Current month-6.17%
1 month-3.08%
3 months-1.22%
6 months+12.73%
Current year-9.56%
1 week 9.72
Extreme 9.72
11.35
1 month 9.31
Extreme 9.31
11.98
Current year 6.52
Extreme 6.52
12.4
1 year 5.23
Extreme 5.23
12.4
3 years 5.23
Extreme 5.23
16
5 years 4.21
Extreme 4.21
20.69
10 years 4.21
Extreme 4.21
36.73
Manager TitleAgeSince
Chief Executive Officer 71 15/08/2016
President 44 07/11/2024
Director of Finance/CFO 58 03/03/2022
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 14/06/2018
Director/Board Member 79 14/06/2018
Date Insider Type Main position Quantity % Market Cap.
24/06/26 Option

Director

2,016 0.0055%
17/06/26 Option

Chairperson

11,618 0.0320%
24/12/25 Buy

Executive/Senior Manager

13,908 0.0461%
Change 5-day change 1-year change 3-year change Capi.($)
-4.51%-17.18%+26.33%-25.93% 255M
+0.89%+7.13%+30.84%+11.26% 224B
-0.92%+6.50%+3.84%-18.78% 146B
+2.00%+8.95%-14.97%+31.77% 142B
+1.45%+4.28%-50.18%+0.31% 74.19B
+1.77%+4.53%+19.83%+17.94% 53.99B
+1.07%+1.51%-13.73%-16.11% 50.85B
+0.52%+7.39%+30.98%+17.84% 42.22B
+0.78%+4.78%+48.59%+42.29% 40.75B
-0.26%+3.54%-0.34%+1.62% 32.86B
Average +0.20%+199.30%+8.12%+6.22% 80.64B
Weighted average by Cap. +0.76%+312.70%+6.54%+8.65%

Financials

2026 *2027 *
Net sales 36.22M 26M 22.53M 21.09M 19.25M 2.48B 36.82M 247M 96.9M 1.24B 97.62M 95.49M 4.14B 59.46M 42.68M 36.99M 34.63M 31.6M 4.07B 60.46M 406M 159M 2.04B 160M 157M 6.8B
Net income -44.08M -31.64M -27.42M -25.67M -23.42M -3.02B -44.82M -301M -118M -1.51B -119M -116M -5.04B -31.27M -22.44M -19.45M -18.21M -16.61M -2.14B -31.79M -214M -83.65M -1.07B -84.27M -82.44M -3.57B
Net Debt - -
Logo Profound Medical Corp.
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
162
Date Price Change Volume
11/08/26 CA$9.740 -4.51% 24,211
10/08/26 CA$10.20 -0.97% 17,085
07/08/26 CA$10.30 -7.21% 26,714
06/08/26 CA$11.10 -0.98% 9,245
05/08/26 CA$11.21 -4.68% 10,390
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
9.740
Average target price
-

Quarterly revenue - Rate of surprise